Clinical Trial Industry News and Trends

R&D Trends

Prev 10 21 22 23 24 25 26 27 28 29 30 Next 10

CureVac, Sanofi Pasteur collaborate in $33 million research project

Tuesday, November 15, 2011 11:20 AM

CureVac has signed several agreements with Sanofi Pasteur, the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive technology platform to the development of vaccines against several infectious diseases.

More... »

Signum, GlaxoSmithKline ink research agreement

Thursday, November 10, 2011 10:09 AM

Signum Biosciences has entered into an agreement with GlaxoSmithKline to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

More... »

Abcodia, Oxford Gene Technology partner to advance pancreatic cancer biomarkers

Wednesday, November 9, 2011 08:42 AM

Abcodia, a company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, and Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, have signed a collaboration aimed at improving the early detection of pancreatic cancer.

More... »

Battelle, Molecular Imaging collaborate in R&D

Tuesday, November 8, 2011 03:07 PM

Battelle, an independent research and development organization, has enhanced its discovery and development services through a collaboration with Molecular Imaging, a provider of small-scale nonclinical in vivo multi-modality imaging services.

More... »

Scientists identify potential cancer drug development target

Friday, November 4, 2011 12:06 PM

Research led by St. Jude Children's Research Hospital scientists has identified an unexpected mechanism facilitating some protein interactions that are the
workhorses of cells and, in the process, identified a potential new cancer
drug development target.

More... »

Life sciences venture capital investing drops 18% in Q3

Thursday, November 3, 2011 01:56 PM

Following two quarters of growth, venture capital funding in the life sciences sector, which includes the biotechnology and medical device industries, fell 18% during the third quarter of 2011, according to a new PwC US report, "Reaching for Growth." The report includes data from the PricewaterhouseCoopers/National Venture Capital MoneyTree Report, based on data from Thomson Reuters.

More... »

Taplmmune, Aeras ink research collaboration

Thursday, November 3, 2011 09:55 AM

TapImmune has signed a research collaboration with Aeras. The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras with the aim of advancing suitable candidates to clinical development. Aeras will conduct all pre-clinical development studies at their laboratories in Rockville, MD.

More... »

Connecticut approves $291 million funding for Jackson Laboratory

Wednesday, November 2, 2011 10:25 AM

The Connecticut legislature has approved $291 million in bond funding to build a new Jackson Laboratory center for personalized medicine and systems genomics in the state.

More... »

Foundation Fighting Blindness invests $8.25 million in gene therapy research

Wednesday, November 2, 2011 09:43 AM

The Foundation Fighting Blindness, a national nonprofit dedicated to advancing sight-saving research, has reported an $8.25 million investment in six new gene therapy research projects that are targeted to have treatments ready for clinical trials within three years. The grants focus on treating a broad range of retinal degenerative diseases and will be allocated through the Foundation's Translational Research Acceleration Program, which funds research efforts with strong, near-term clinical potential.

More... »

Oxford BioMedica, Mayo Clinic collaborate in glaucoma research

Monday, October 31, 2011 11:04 AM

Oxford BioMedica has entered into a research and development collaboration with Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and Oxford BioMedica will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica's proprietary LentiVector gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene in order to reduce intraocular pressure. The collaboration includes an option for exclusive US rights to license Mayo Clinic's glaucoma technology, which Oxford BioMedica can exercise upon completion of pre-clinical studies under confidential terms agreed by Mayo Clinic and Oxford BioMedica.

More... »